Degarelix approved for advanced prostate cancer

Degarelix (injectable gonadotropin-releasing hormone (GnRH) receptor antagonist, from Ferring Pharmaceuticals) has been approved by the FDA for treatment of hormonally-sensitive advanced prostate cancer. This approval was based on results from a Phase III, 12-month, randomized, open-label, parallel-group clinical trial comparing degarelix with monthly leuprolide in patients with histologically confirmed prostate cancer. The study showed degarelix to be at least as effective as leuprolide in achieving and maintaining castrate levels of testosterone.

For more information call (888) FERRING or visit www.FerringUSA.com.